thymosin beta-4 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-20. Numbers and descriptions here follow the published literature rather than marketing material.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
High-level waste (HLW) is produced by nuclear reactors and the reprocessing of nuclear fuel. The exact definition of HLW differs internationally. After a nuclear fuel rod serves one fuel cycle and is removed from the core, it is considered HLW. Spent fuel rods contain mostly uranium with fission products and transuranic elements generated in the reactor core. Spent fuel is highly radioactive and often hot. HLW accounts for over 95% of the total radioactivity produced in the process of nuclear electricity generation but it contributes to less than 1% of volume of all radioactive waste produced in the UK. Overall, the 60-year-long nuclear program in the UK up until 2019 produced 2150 m3 of HLW. The radioactive waste from spent fuel rods consists primarily of cesium-137 and strontium-90, but it may also include plutonium, which can be considered transuranic waste. The half-lives of these radioactive elements can differ quite extremely. Some elements, such as cesium-137 and strontium-90 have half-lives of approximately 30 years. Meanwhile, plutonium has a half-life that can stretch to as long as 24,000 years. The amount of HLW worldwide is increasing by about 12,000 tonnes per year. A 1000-megawatt nuclear power plant produces about 27 tonnes of spent nuclear fuel (unreprocessed) every year. For comparison, the amount of ash produced by coal power plants in the United States is estimated at 130,000,000 t per year and fly ash is estimated to release 100 times more radiation than an equivalent nuclear power plant.
Dapagliflozin was authorized for medical use in the European Union in November 2012. It is sold in a number of European countries. Dapagliflozin was approved for medical use in the United States in January 2014. In 2020, the US FDA expanded the indications for dapagliflozin to include treatment for adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure. It is the first in this particular drug class, sodium-glucose co-transporter 2 inhibitors, to be approved to treat adults with New York Heart Association's functional class II-IV heart failure with reduced ejection fraction. In the DAPA‑HF clinical trial, when dapagliflozin was added to standard therapy in adults with symptomatic heart failure and reduced ejection fraction, the risk of worsening heart failure or cardiovascular death was reduced. It also reduced the risk of death from any cause (approximately 17% lower risk) compared with placebo over an average of about 18 months. In DECLARE‑TIMI 58, a clinical trial which included adults with type 2 diabetes and cardiovascular risk, dapagliflozin reduced heart failure hospitalisations and improved the combined outcome of death from a heart related cause or heart failure hospitalisation. However, dapagliflozin did not reduce the overall number of deaths from any cause compared with placebo when all participants were considered together. The safety and effectiveness of dapagliflozin were evaluated in a randomized, double-blind, placebo-controlled study of 4,744 participants.
The acidity of lactic acid impedes biological processes. This can be beneficial to the fermenting organism as it drives out competitors that are unadapted to the acidity. As a result, the food will have a longer shelf life (one reason foods are purposely fermented in the first place); however, beyond a certain point, the acidity starts affecting the organism that produces it. The high concentration of lactic acid (the final product of fermentation) drives the equilibrium backwards (Le Chatelier's principle), decreasing the rate at which fermentation can occur and slowing down growth. Ethanol, into which lactic acid can be easily converted, is volatile and will readily escape, allowing the reaction to proceed easily. CO2 is also produced, but it is only weakly acidic and even more volatile than ethanol. Acetic acid (another conversion product) is acidic and not as volatile as ethanol; however, in the presence of limited oxygen, its creation from lactic acid releases additional energy. It is a lighter molecule than lactic acid, forming fewer hydrogen bonds with its surroundings (due to having fewer groups that can form such bonds), thus is more volatile and will also allow the reaction to proceed more quickly. If propionic acid, butyric acid, and longer monocarboxylic acids are produced, the amount of acidity produced per glucose consumed will decrease, as with ethanol, allowing faster growth.
This was announced after the BBC had experimented with 8K during the London Olympics. On January 27, 2013, Asahi Shimbun reported that 4K Ultra HD satellite broadcasts would start in Japan with the 2014 FIFA World Cup. Japan's Ministry of Internal Affairs and Communications decided on this move to stimulate demand for 4K Ultra HD TVs. On February 21, 2013, Sony announced that the PlayStation 4 would support 4K resolution output for photos and videos but wouldn't render games at that resolution. On March 26, 2013, the Advanced Television Systems Committee (ATSC) announced a call for proposals for the ATSC 3.0 physical layer that specifies support for 3840 × 2160 resolution at 60 fps. On 11 April 2013, Bulb TV created by Canadian entrepreneur Evan Kosiner announced a 4K linear channel and VOD content to cable and satellite companies in North America. The channel planned to be licensed by the Canadian Radio-Television and Telecommunications Commission to provide educational content. On April 19, 2013, SES announced the first Ultra HD transmission using the High Efficiency Video Coding(HEVC) standard. The transmission had a resolution of 3840 × 2160 and a bit rate of 20 Mbit/s. On May 9, 2013, NHK and Mitsubishi Electric announced that they had jointly developed the first HEVC encoder for 8K Ultra HD TV, which is also called Super Hi-Vision (SHV). The HEVC encoder supports the Main 10 profile at Level 6.1 allowing it to encode 10 bpc video with a resolution of 7680 × 4320 at 60 fps.
Sources: en.wikipedia.org
== Use as an educational tool == The AIDA software comes with forty educational case scenarios as standard, each of which represents a 'snapshot' of the metabolic status of a typical person with respect to insulin-dependent type 1 diabetes mellitus. It is easy for users to add or create further case scenarios, as required. Examples of the application of AIDA as an educational tool can be found in various published journal articles.
=== EC 1.18.1 With NAD+ or NADP+ as acceptor === EC 1.18.1.1: rubredoxin—NAD+ reductase EC 1.18.1.2: ferredoxin—NADP+ reductase EC 1.18.1.3: ferredoxin—NAD+ reductase EC 1.18.1.4: rubredoxin—NAD(P)+ reductase EC 1.18.1.5: Putidaredoxin—NAD+ reductase EC 1.18.1.6: adrenodoxin-NADP+ reductase EC 1.18.1.7: ferredoxin—NAD(P)+ reductase (naphthalene dioxygenase ferredoxin-specific) EC 1.18.1.8: Now EC 7.2.1.2, ferredoxin—NAD+ oxidoreductase (Na+-transporting)
== Example == This is an example of an esterification reaction where one molecule acetic acid (also called ethanoic acid) reacts with one molecule ethanol, yielding one molecule ethyl acetate (a bimolecular second-order reaction of the type A + B → C):
LL-37 has also been found to be a common auto-antigen in psoriasis; T-cells specific to LL-37 were found in the blood and skin in two thirds of patients with moderate to severe psoriasis. LL-37 binds to the peptide Ab, which is associated with Alzheimer's disease. An imbalance between LL-37 and Ab may be a factor affecting AD-associated fibrils and plaques. Chronic, oral Porphyromonas gingivalis, and herpesvirus (HSV-1) infections may contribute to the progression of Alzheimer's dementia.
α-Ketoglutaric acid (AKG) is an organic compound with the formula HO2CCO(CH2)2CO2H. A white, nontoxic solid, it is a common dicarboxylic acid. Relevant to its biological roles, it exists in water as its conjugate base α-ketoglutarate. It is also classified as a 2-ketocarboxylic acid. β-Ketoglutaric acid is an isomer. "Ketoglutaric acid" and "ketoglutarate", when not qualified as α or β, almost always refers respectively to α-ketoglutaric acid or α-ketoglutarate. α-Ketoglutarate is an intermediate in the citric acid cycle, a set of cyclic reactions that supplies energy to cells. It is also an intermediate in or product of several other metabolic pathways. These include its being a component of metabolic pathways that: make amino acids and in the process regulate the cellular levels of carbon, nitrogen, and ammonia; reduce the cellular levels of potentially toxic reactive oxygen species; and synthesize the neurotransmitter γ-aminobutyric acid (GABA). A large body of preclinical (i.e., conducted in animal models of disease or on animal or human tissues) research has been conducted on the role of endogenous (generated within the body) α-ketoglutarate. A small amount of preclinical research has been done to determine the effects of providing additional exogenous α-ketoglutarate to biological systems. There is currently no randomized controlled trials showing α-ketoglutarate to have any pharmacological (drug-like) effects on humans. The Food and Drug Administration classifies α-ketoglutaric acid as "503A Category 3: Bulk Drug Substances Nominated Without Adequate Support".
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
Sealed, dry and protected from light at reduced temperature is the usual laboratory convention. Allowing a cold vial to reach room temperature before opening limits condensation. Repeated opening exposes the powder to moisture and should be minimised.